Plain-English translation of NCT05934487 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The PROACTIVE-HF-2 trial is testing the Cordella™ Pulmonary Artery Sensor System, a tiny wireless device that measures pressure in the heart's blood vessels. Doctors think this real-time information might help them adjust your medications more precisely and catch problems earlier, potentially preventing hospitalizations. The trial will compare how well the treatment works when doctors can see this sensor data versus when they manage your heart failure using traditional methods alone.
Heart failure is unpredictable, and by the time patients feel worse or go to the hospital, damage has often already occurred. This trial aims to see whether having continuous, real-time pressure information from inside the heart allows doctors to prevent crises before they happen and manage the condition more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive a small wireless sensor implant during a minimally invasive procedure, similar to a heart catheterization. After implantation, you'll use a handheld reader device to check your heart's pressure readings daily by holding it against your chest for about 2 minutes. Depending on which study group you're in, your doctor will either use this daily pressure data to fine-tune your medications according to specific protocols, or will manage your care using traditional methods until the study's main checkpoint at 24 months. You'll attend regular follow-up visits at the hospital to monitor your progress.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States